Why CVS Health stock could appreciate 35% from here
Discover why TD Cowen sees 35% upside in CVS Health stock, driven by Medicare Advantage improvements and bullish technical ...
CVS is under pressure and considering a breakup. Here's why that could be risky
As it seeks to claw back faith with Wall Street, the company is considering breaking itself up. CVS has engaged advisors in a ...
CVS Stock Can Gain 35% From Here, Analyst Says. Here’s How.
CVS Health stock climbed Friday after an analyst predicted strong earnings growth in 2025, driven partly by its Medicare ...
CVS Stock Hits 50-Day SMA on Split Rumors: How Should You Play?
The market speculates that following the FTC notice, several investors are pushing CVS Health to go for segment breakups.
CVS Health to lay off nearly 3,000 workers in cost-cutting drive
CVS Health is planning to cut about 2,900 jobs in an effort to slash costs, the US health care company said Tuesday.
CVS Health获得买入评级上调，目标价上调
TD Cowen上调了对CVS Health (NYSE: CVS)的评级，将该股票从持有上调至买入。该公司还将CVS股票的目标价从59.00美元上调至85.00美元，显示出投资者可能获得可观的上涨空间。 这次股票前景的修正是在CVS发布2025年Medicare Advantage (MA)计划福利后做出的。据分析师称，该公司大幅削减了非处方药(OTC)福利和牙科津贴。此外，2025年评级为4星 ...
Forbes3 天
Should You Pick CVS Stock At $65?
OCEANSIDE, NEW YORK - AUGUST 23: A general view of a CVS Pharmacy store on August 23, 2024 in ... [+] Oceanside, New York.
CVS, Considering a Breakup, Will Find It’s Hard to Do
Splitting up the healthcare company into stand-alone pharmacy or health insurance businesses could leave them struggling.
Exclusive: CVS explores options including potential break-up, sources say
CVS Health is exploring options that could include a break-up of the company to separate its retail and insurance units, as ...
西维斯健康股价上涨1.37%：财报解读与市场前景展望
2024年10月4日，西维斯健康（CVS Health）股票开盘上涨1.37%，盘中价格达到每股63.78美元。在全球经济形势复杂多变的背景下，这是一个不容忽视的市场动态。结合即将发布的财报和分析师评估，这一现象引发了投资者和市场观察者的广泛关注。那么，这一波动背后隐藏着怎样的故事？
Glenview Capital: We Don’t Want CVS Health Broken Up
Glenview Capital Management — a hedge fund that has been subject of certain media reports that it was pushing CVS Health ...
摩根士丹利维持CVS Health股票增持评级
周三，摩根士丹利重申了对CVS Health (NYSE:CVS)股票的增持评级，目标价保持在65.00美元。该公司的分析表明，尽管CVS Health未来结构存在不确定性，但其股票仍有轻微上涨潜力。这一评级来自于有关CVS可能考虑分拆零售和保险业务的猜测。 摩根士丹利的分析师提供了一个假设的分部估值(SOTP)分析，该分析暗示基本情况下的股价为66美元，略高于当前目标价和市场价值。这一分析是在有 ...